September 11-13, 2022
Hero background

Breakout Session

AI and Drug Development: IP Implications for Protecting AI Discoveries

September 12, 2022 @ 3:30 PM CST – Knowles IP Strategies Ballroom

3:30 PM CT
September 12, 2022

Knowles IP Strategies Ballroom
Breakout Session

AI and Drug Development: IP Implications for Protecting AI Discoveries

View Session Speakers

CLEAs with many industries, Artificial intelligence (AI) enabled solutions are revolutionizing every stage of the drug development process to accelerate it and improve its efficiency. As biopharmaceutical companies increasingly rely on AI, there is a real possibility that a drug substance, drug product, or a drug formulation soon will be invented by AI. If and when that happens, who owns the intellectual property for those inventions?

Patent Offices around the world, including the United States Patent and Trademark Office, have determined that an AI cannot be listed as an inventor. If AI-created inventions cannot be patented, will the biopharmaceutical companies be interested in pursuing inventions using AI to develop drug products?

Our panel will tackle these and other complicated and thorny legal issues presented by the use of AI in the drug development process.

Materials*

Protecting Artificial Intelligence Inventions in Drug Development

CAFC ‘Unambiguously’ Backs USPTO in AI as Inventor Fight

* A Note on Materials: We apply for MCLE, which requires substantive writing on the topic covered. The materials provided below, often published by IPWatchdog.com authors and contributors, relate to the topic but are not intended to pigeon-hole guest speakers in any way. They are hopefully informative, and the articles we select have to date always been sufficient to satisfy MCLE authorities.



Add to Calendar 12/01/2022 8:12 AM America/Chicago AI and Drug Development: IP Implications for Protecting AI Discoveries

As with many industries, Artificial intelligence (AI) enabled solutions are revolutionizing every stage of the drug development process to accelerate it and improve its efficiency. As biopharmaceutical companies increasingly rely on AI, there is a real possibility that a drug substance, drug product, or a drug formulation soon will be invented by AI. If and when that happens, who owns…

Session Speakers

Sharon Crane

Member

Rothwell, Figg, Ernst and Manbeck, P.C.

Dina Blikshteyn

Dina Blikshteyn

Counsel and Co-Chair, Artificial Intelligence Practice Group

Haynes and Boone, LLP

Anthony Prosser, Ph.D.

Anthony R. Prosser, Ph.D.

Patent Attorney

Knowles Intellectual Property Strategies

Eyal Barash

Patent Attorney and Founder

Barash Law LLC